Literature DB >> 22849964

Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.

Edwin DeJesus1, Jürgen K Rockstroh, Jeffrey L Lennox, Michael S Saag, Adriano Lazzarin, Jing Zhao, Hong Wan, Anthony J Rodgers, Monica L Walker, Michael Miller, Mark J DiNubile, Bach-Yen Nguyen, Hedy Teppler, Randi Leavitt, Peter Sklar.   

Abstract

We compared 4 years of antiretroviral therapy with tenofovir/emtricitabine and either raltegravir or efavirenz from the ongoing STARTMRK study of treatment-naïve HIV-infected patients. Through 192 weeks, raltegravir produced durable and consistent viral suppression and immune restoration compared with efavirenz irrespective of baseline demographic and prognostic factors, including in patients with high viral loads.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22849964     DOI： 10.1310/hct1304-228

Source DB:  PubMed          Journal:  HIV Clin Trials        ISSN： 1528-4336


  9 in total

1.  Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.

Authors:  Kristen N Andreatta; Derrick D Goodman; Michael D Miller; Kirsten L White
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

2.  Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings.

Authors:  Robin M Nance; Vani Vannappagari; Kimberly Smith; Catherine B Johannes; Brian Calingaert; Catherine W Saltus; Kenneth H Mayer; Bridget M Whitney; Benigno Rodriguez; Richard D Moore; Joseph J Eron; Elvin Geng; William Christopher Mathews; Michael J Mugavero; Michael S Saag; Mari M Kitahata; Joseph A C Delaney; Heidi M Crane
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-15       Impact factor: 3.731

3.  HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015: A Cohort Study.

Authors:  Robin M Nance; J A Chris Delaney; Jane M Simoni; Ira B Wilson; Kenneth H Mayer; Bridget M Whitney; Frances M Aunon; Steven A Safren; Michael J Mugavero; W Christopher Mathews; Katerina A Christopoulos; Joseph J Eron; Sonia Napravnik; Richard D Moore; Benigno Rodriguez; Bryan Lau; Rob J Fredericksen; Michael S Saag; Mari M Kitahata; Heidi M Crane
Journal:  Ann Intern Med       Date:  2018-08-21       Impact factor: 25.391

4.  Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.

Authors:  Kristen N Andreatta; Michael D Miller; Kirsten L White
Journal:  Antimicrob Agents Chemother       Date:  2015-11-16       Impact factor: 5.191

5.  Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan.

Authors:  Sui-Yuan Chang; Pi-Han Lin; Chien-Lin Cheng; Mao-Yuan Chen; Hsin-Yun Sun; Szu-Min Hsieh; Wang-Huei Sheng; Yi-Ching Su; Li-Hsin Su; Shu-Fang Chang; Wen-Chun Liu; Chien-Ching Hung; Shan-Chwen Chang
Journal:  Sci Rep       Date:  2016-10-25       Impact factor: 4.379

6.  Absence of Integrase Inhibitor-Associated Resistance Among Antiretroviral Therapy-Naïve HIV-1-Infected Adults in Guangdong Province, China, in 2018.

Authors:  Yun Lan; Linghua Li; Weilie Chen; Xizi Deng; Junbin Li; Qinghong Fan; Xiaoli Cai; Weiping Cai; Fengyu Hu
Journal:  Infect Drug Resist       Date:  2020-12-08       Impact factor: 4.003

7.  Clinical Effectiveness of Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada.

Authors:  Haidong Lu; Stephen R Cole; Daniel Westreich; Michael G Hudgens; Adaora A Adimora; Keri N Althoff; Michael J Silverberg; Kate Buchacz; Jun Li; Jessie K Edwards; Peter F Rebeiro; Viviane D Lima; Vincent C Marconi; Timothy R Sterling; Michael A Horberg; M John Gill; Mari M Kitahata; Joseph J Eron; Richard D Moore
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079

8.  The Global Health Impact Index: Promoting Global Health.

Authors:  Nicole Hassoun
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

9.  AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000-2008: hospital-based cohort studies.

Authors:  Paula Mendes Luz; Mathias Bruyand; Sayonara Ribeiro; Fabrice Bonnet; Ronaldo Ismério Moreira; Mojgan Hessamfar; Dayse Perreira Campos; Carine Greib; Charles Cazanave; Valdilea Gonçalves Veloso; François Dabis; Beatriz Grinsztejn; Geneviève Chêne
Journal:  BMC Infect Dis       Date:  2014-05-21       Impact factor: 3.090
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.